- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00982293
The Application of Extremely Low Level Magnetic Fields as Adjunctive Treatment for Type II Diabetes
May 4, 2011 updated by: pico-tesla Magnetic Therapies, LLC
A Randomized, Double Blind, Placebo Controlled Study of the Application of Magnetic Fields Using the Resonator in Adjunctive Management of Type 2 Diabetes Mellitus, Pilot Study II
The purpose of this study is to see if using a device called the Resonator, that puts out very low level electromagnetic fields, effects blood glucose and A1c levels in people with Type 2 Diabetes.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
The purpose of this pilot study is to determine whether application of magnetic fields generated by the Resonator TM, as an adjunctive therapy to oral medications results in statistically significant reductions in fasting blood glucose levels, post prandial glucose levels and hemoglobin A1c levels.
The study will also investigate any induced changes in serum lipids.
Study Type
Interventional
Enrollment (Anticipated)
165
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Colorado
-
Littleton, Colorado, United States, 80120
- pico-tesla Magnetic Therapies
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Current diagnosis of Type 2 Diabetes Mellitus with a hemoglobin A1c level above 7.5%, despite management of diabetes with diet and/or medication.
- Subject currently performs routine finger stick blood sugar testing as part of his or her current diabetes disease management regimen.
- Subject is ambulatory
- Subject is on stable oral medication regimen without significant side effects for at least three (3) months (stable insulin regimen NOT permissible); willingness and ability to maintain the stable oral medication regimen throughout the course of the study. If on agents suspected of contributing to hyperglycemia(see list below), subject must have been on a stable dose of this(these) agent(s) for 6 months prior to study initiation.
- Hemoglobin A1c levels within a 0.8 % range of patient mean A1c level for the last two documented determinations, that must be within 2 years of the baseline testing date.
- Willingness to test finger stick blood sugars according to prescribed protocol.
- Willingness to have lab test blood draws performed according to prescribed protocol
- Willingness to maintain stable diet and activity regimen for the duration of the study.
- Willing and able to abstain from partaking in any non-essential (not physician ordered) existing or new treatments to improve serum blood sugar levels
- Willing and able to abstain from all medications that could affect diabetes mellitus and/or any of its associated symptoms for the duration of the study
- Adequate contraceptive measures for females subjects
- Any ethnic background
Exclusion Criteria:
- Change in medical regimen within 3 months prior to initiation of study.
- Any signs of type 1 diabetes mellitus (including any history of ketoacidosis or new requirement for insulin therapy within the 6 month period prior to study initiation).
- Active significant infectious process within 3 weeks of study initiation causing wide fluctuations in finger stick blood sugar level
- Change in BMI of greater than 6 % within a 3 month period prior to study initiation
- Any planned revascularization procedure.
- Symptomatic congestive heart failure.
- Leg or foot ulceration or open wounds
- Gangrene.
- History of intermittent claudication
- Hemodialysis
- Currently being treated for malignancy
- Currently being treated with oral or intravenous catabolic steroids
- Reported consumption of more than 14 alcoholic drinks per week.
- Pregnant, breast feeding, or planning pregnancy prior to the end of participation
- Developmental disability or cognitive impairment that would make it difficult for the subject to partake in the clinical study, including adequate comprehension of the informed consent form and ability to record the necessary measurements
- Uncontrolled hypertension
- Uncontrolled atrial fibrillation or other uncontrolled arrythmias, e.g. tachycardia, bradycardia
- Uncontrolled seizure disorder
- Uncontrolled, unstable, or untreated medical conditions which may significantly impact the subject's health or ability to complete the entire study, in the opinion of the investigator.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Active fields
|
Low level electromagnetic fields for whole body immersion, 3 times weekly for 13 weeks (39) sessions of approximately 11/2 hours each.
|
Sham Comparator: Inactive device
Placebo treated group, will receive the 3 times weekly for 13 weeks (39) sessions, however, the device will not be "on".
|
Treatment, 3 times weekly for 13 weeks (39) sessions - device will not be "on"
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The primary outcome measure is the improvement in Subject's hemoglobin A1c level after 13 weeks of treatment compared to baseline.
Time Frame: baseline, end of treatment (13 weeks) and 3 months post treatment
|
baseline, end of treatment (13 weeks) and 3 months post treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2009
Primary Completion (Anticipated)
May 1, 2011
Study Completion (Actual)
May 1, 2011
Study Registration Dates
First Submitted
September 21, 2009
First Submitted That Met QC Criteria
September 22, 2009
First Posted (Estimate)
September 23, 2009
Study Record Updates
Last Update Posted (Estimate)
May 5, 2011
Last Update Submitted That Met QC Criteria
May 4, 2011
Last Verified
May 1, 2011
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 09109-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes
-
Antonio Di MauroCompletedType-2 DiabetesItaly
-
DiaMedica Therapeutics IncCompletedDiabetes Type 2Netherlands
-
RenJi HospitalUnknownType 2 Diabetes.China
-
University of Erlangen-Nürnberg Medical SchoolCompletedType 2-diabetesGermany
-
Chengdu Brilliant Pharmaceutical Co., Ltd.Not yet recruitingType 2 Diabetes Mellitus
-
Nanjing First Hospital, Nanjing Medical UniversityRecruitingType 2 Diabetes MellitusChina
-
Xiangya Hospital of Central South UniversityRecruitingType 2 Diabetes MellitusChina
-
University of Alabama at BirminghamCompletedType 2 Diabetes MellitusUnited States
-
Imperial College LondonAstraZeneca; Huma; North West London Collaboration of CCGs (NWL CCGs); Imperial...CompletedType 2 Diabetes MellitusUnited Kingdom
-
Universiti Sains MalaysiaCompleted
Clinical Trials on Resonator device
-
pico-tesla Magnetic Therapies, LLCWithdrawnOsteoarthritis of the HipUnited States
-
pico-tesla Magnetic Therapies, LLCUnknownQuality of Life | Parkinson's DiseaseUnited States
-
pico-tesla Magnetic Therapies, LLCCompletedParkinson's Disease
-
pico-tesla Magnetic Therapies, LLCCompletedType II Diabetes MellitusUnited States
-
pico-tesla Magnetic Therapies, LLCCompleted
-
pico-tesla Magnetic Therapies, LLCUnknownAlzheimer's DementiaUnited States
-
pico-tesla Magnetic Therapies, LLCWithdrawn
-
BioNumerik Pharmaceuticals, Inc.Lantern Pharma Inc. became Sponsor of Tavocept (BNP7787) IND 051014 as of...CompletedBreast Neoplasms | Breast Diseases | Metastases, Neoplasm
-
Facet TechnologiesLifeScanCompletedDiabetesUnited States
-
AOTI Ltd.UnknownDiabetic Foot UlcerUnited Kingdom, United States, Germany, France, Luxembourg